Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Goldschmidt

Showing results (461-470 of 472) with videos related to

Pageof 48
Sort By:
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Bone Marrow Transplantation|May 16, 2017
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trialS Huhn, N Weinhold, J Nickel, et al.
Leukemia|December 28, 2016
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myelomaM I da Silva Filho, A Försti, N Weinhold, et al.
Pigment Cell & Melanoma Research|October 17, 2013
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanomaR Mark Simpson, Boris C Bastian, Helen T Michael, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Leukemia|August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialH Goldschmidt, H M Lokhorst, E K Mai, et al.
Blood Cancer Journal|June 17, 2017
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approachM Went, A Sud, P J Law, et al.
Veterinary Pathology|November 11, 2010
Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behaviorM Kiupel, J D Webster, K L Bailey, et al.
Leukemia|June 17, 2017
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyS K Kumar, M A Dimopoulos, E Kastritis, et al.
Pageof 48

Showing results (461-470 of 472) with videos related to

Sort By:
Pageof 48
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Bone Marrow Transplantation|May 16, 2017
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trialS Huhn, N Weinhold, J Nickel, et al.
Leukemia|December 28, 2016
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myelomaM I da Silva Filho, A Försti, N Weinhold, et al.
Pigment Cell & Melanoma Research|October 17, 2013
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanomaR Mark Simpson, Boris C Bastian, Helen T Michael, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Leukemia|August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialH Goldschmidt, H M Lokhorst, E K Mai, et al.
Blood Cancer Journal|June 17, 2017
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approachM Went, A Sud, P J Law, et al.
Veterinary Pathology|November 11, 2010
Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behaviorM Kiupel, J D Webster, K L Bailey, et al.
Leukemia|June 17, 2017
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyS K Kumar, M A Dimopoulos, E Kastritis, et al.
Pageof 48